Randomized trial · people

Tirzepatide: HbA1c fell up to 2.07% at 40 weeks in SURPASS-1

Checked against the paper Randomized trialPublished by PepVault

The takeaway

In adults with type 2 diabetes, all 3 tirzepatide doses lowered blood sugar and body weight more than placebo over 40 weeks, with mostly gut-related side effects.

Kind
Randomized trial
Studied in
People
Number studied
478
Published
2021
Journal
Lancet

What they tested

Does tirzepatide taken on its own lower HbA1c (glycated hemoglobin) more than placebo in adults with type 2 diabetes not controlled by diet and exercise alone?

How the study was done

A double-blind, randomized, placebo-controlled phase 3 trial in 478 adults with type 2 diabetes who had never used injectable diabetes drugs, at 52 sites in India, Japan, Mexico and the USA. Participants got once-weekly tirzepatide at 5, 10 or 15 mg, or placebo, for 40 weeks.

A woman in glasses at a kitchen table with a laptop, a mug and her phone

Model. Individual results vary.

PepVault for iPhone

Taking tirzepatide? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

What they found

HbA1c dropped by 1.87% in the 5 mg arm, 1.89% in the 10 mg arm and 2.07% in the 15 mg arm, while it rose by 0.04% on placebo. An HbA1c below 7.0% was reached by 87-92% of people on tirzepatide versus 20% on placebo, and 31-52% on tirzepatide got below 5.7% versus 1% on placebo. Weight loss grew with dose, ranging from 7.0 to 9.5 kg. The most common side effects were gut problems that were mild to moderate and short-lived, such as nausea (12-18% vs 6%), and no clinically significant or severe low blood sugar was seen on tirzepatide.

What it doesn’t show

The trial lasted 40 weeks and compared tirzepatide alone only with placebo, in adults whose diabetes was not controlled by diet and exercise and who had not used injectable diabetes drugs. It was funded by Eli Lilly and Company.

The paper

Rosenstock et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet. 2021.

The compound

More studies on Tirzepatide

Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.

Track it in the app

PepVault for iPhone

Taking tirzepatide? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo